What is Leerink Partnrs' Estimate for NovoCure Q1 Earnings?

NovoCure Limited (NASDAQ:NVCR - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for NovoCure in a research note issued on Thursday, February 27th. Leerink Partnrs analyst J. Chang anticipates that the medical equipment provider will post earnings per share of ($0.44) for the quarter. The consensus estimate for NovoCure's current full-year earnings is ($1.30) per share. Leerink Partnrs also issued estimates for NovoCure's Q4 2025 earnings at ($0.52) EPS and FY2026 earnings at ($2.04) EPS.

NovoCure (NASDAQ:NVCR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.27). The business had revenue of $161.27 million during the quarter, compared to analysts' expectations of $161.30 million. NovoCure had a negative net margin of 25.93% and a negative return on equity of 41.48%.

A number of other analysts have also recently commented on NVCR. Wedbush restated a "neutral" rating and issued a $29.00 price objective on shares of NovoCure in a research report on Monday, January 13th. StockNews.com cut NovoCure from a "hold" rating to a "sell" rating in a research report on Monday. Evercore ISI raised NovoCure from an "in-line" rating to an "outperform" rating and lifted their price target for the stock from $18.00 to $30.00 in a research note on Monday, December 2nd. Piper Sandler lifted their price target on NovoCure from $28.00 to $42.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price target on shares of NovoCure in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $32.67.

Remove Ads

NovoCure Price Performance

Shares of NovoCure stock traded up $0.11 on Monday, reaching $19.26. The company's stock had a trading volume of 858,172 shares, compared to its average volume of 1,252,926. The company has a market capitalization of $2.12 billion, a P/E ratio of -13.76 and a beta of 0.63. NovoCure has a 52-week low of $11.70 and a 52-week high of $34.13. The stock has a 50-day moving average price of $24.58 and a 200-day moving average price of $21.43. The company has a quick ratio of 1.44, a current ratio of 1.49 and a debt-to-equity ratio of 0.27.

Hedge Funds Weigh In On NovoCure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mackenzie Financial Corp acquired a new position in NovoCure during the fourth quarter worth $203,000. GF Fund Management CO. LTD. acquired a new position in NovoCure during the fourth quarter worth $68,000. Soleus Capital Management L.P. acquired a new position in NovoCure during the fourth quarter worth $81,643,000. Teza Capital Management LLC boosted its stake in NovoCure by 573.0% during the fourth quarter. Teza Capital Management LLC now owns 100,200 shares of the medical equipment provider's stock worth $2,986,000 after buying an additional 85,312 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. boosted its stake in NovoCure by 264.6% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,901 shares of the medical equipment provider's stock worth $206,000 after buying an additional 5,008 shares during the last quarter. Institutional investors and hedge funds own 84.61% of the company's stock.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.